NTV Asset Management LLC Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

NTV Asset Management LLC decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 2.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,300 shares of the company’s stock after selling 200 shares during the period. NTV Asset Management LLC’s holdings in Novo Nordisk A/S were worth $755,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Xponance Inc. purchased a new position in Novo Nordisk A/S during the third quarter worth about $248,000. Stratos Wealth Partners LTD. raised its stake in shares of Novo Nordisk A/S by 228.9% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 17,857 shares of the company’s stock worth $1,624,000 after buying an additional 12,427 shares in the last quarter. Stratos Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $237,000. Bank of New York Mellon Corp boosted its stake in shares of Novo Nordisk A/S by 97.1% in the third quarter. Bank of New York Mellon Corp now owns 863,598 shares of the company’s stock valued at $78,536,000 after buying an additional 425,392 shares in the last quarter. Finally, Bailard Inc. grew its holdings in Novo Nordisk A/S by 104.7% during the third quarter. Bailard Inc. now owns 8,191 shares of the company’s stock worth $745,000 after acquiring an additional 4,189 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Finally, BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Down 0.8 %

Novo Nordisk A/S stock traded down $0.97 during midday trading on Friday, hitting $123.05. 5,932,926 shares of the company were exchanged, compared to its average volume of 3,905,318. The company’s fifty day moving average price is $127.20 and its 200-day moving average price is $113.10. The company has a market cap of $552.19 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. On average, research analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.